Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib vs docetaxel in previously treated KRAS p.G12C-mutated metastatic NSCLC (CodeBreaK 200)
2023-508214-42-00Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started Feb 2024; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508214-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508214-42-00.